Companion Diagnostics

News on companion diagnostics and drug/test co-development.

The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.

The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.

The agency cleared the company's C-reactive protein, which is based on its Multi-Array technology used by life science researchers for 20 years.